Lyell Immunopharma (LYEL) Share-based Compensation (2020 - 2026)

Lyell Immunopharma has reported Share-based Compensation for 6 years, with the latest figure at $25.6 million in Q4 2025.

• Quarterly Share-based Compensation rose 216.33% year-over-year to $25.6 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $35.8 million (up 19.3% YoY) and the FY2025 annual result came in at $41.8 million, up 26.2% from the prior year.
• Share-based Compensation rose to $25.6 million in Q4 2025 per LYEL's latest filing, from $5.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $116.0 million in Q2 2021 and troughed at -$22.0 million in Q2 2022.
• A 5-year average of $18.2 million and a median of $8.5 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation slumped 118.99% in 2022, then surged 10391.01% in 2023.
• Over 5 years, Share-based Compensation stood at $13.0 million in 2021, then surged by 525.34% to $81.6 million in 2022, then slumped by 89.62% to $8.5 million in 2023, then declined by 4.49% to $8.1 million in 2024, then soared by 216.33% to $25.6 million in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered $25.6 million, $5.2 million, and $5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.